الفهرس 
Title : The impact of sofosbuvir containing regimens on outcomes of a cohort of Egyptian patients with chronic hepatitis c virus induced cirrhosis with mild decompensation
AbstractOnly 14 pages are availabe for public view
 |  | from | 145 |  |  |
| | | from | 145 | | |
Abstract
Back ground: chronic hepatitis C (CHC) is a major health problem in Egypt. The appearance of DAAs have revolutionizes treatment for patients with CHC including patients with decompensated cirrhosis.Since November 2015 SOF/DAC ± RBV became the main line of therapy in Egypt. Aim: In this study we aime at evaluating the efficacy, safety and tolerability of SOF/DAC ± RBV in a cohort of Egyptian patients with CHC induced cirrhosis with mild decompensation. Method: This study was conducted on 120 patients with CHC induced cirrhosis with mild decompensation (class B) all received treatment with SOF (400mg) and DAC (60 mg) once daily ± ribavirin. 80.8% of patients were treatment naïve while 19.2% were experienced. 71.6% of patients received treatment for 12 weeks and 28.4% of them received treatment for 24 weeks. Treatment response was assessed by quantitative serum PCR for HCV RNA at baseline, at the end of therapy and 12 weeks after the end of therapy (SVR 12). Results: SVR12 rate was 82.9%, intolerance rate was 8.1%, non-response rate was 2.7% & relapse rate was 2.7%.SVR12 rate was significantly higher among patients with higher baseline WBCs count and lower among patients with child pugh class B9. All intolerant patients had ascites (P = 0.02). There was a significant decline in the level of haemoglubin, ALT& AST and serum bilirubin(P <0.001) and a significant increase in albumin level (P < 0.001) at the end of treatment when compared to their levels at baseline